Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Penetration-promoting and Imageable Polymeric Micelles as a Platform Technology for Individualized and Improved Tumor-targeted Drug Delivery

Project description

Personalised cancer treatment that hits the spot – and penetrates it

The exciting potential of therapeutic nanomaterials carrying drug cargo to targeted cancer cells in tumours and metastases has not been realised due to variability in nanomedicine accumulation in target tissues and poor penetration of target tissues once accumulated there. The European Research Council-funded PIcelles project will address this challenge with novel polymeric micelles. They can be easily and stably loaded with drugs. A peptide on their shell will promote targeting and penetration. Their radiolabelling will enable non-invasive imaging of target accumulation. The project will enable the team to optimise the pioneering platform and prepare for commercialisation, unleashing a new era in targeted drug delivery of anticancer agents.

Objective

PIcelles will assess the commercial viability of a novel theranostic nanoformulation for anticancer therapy. Current nanomedicine platforms are not able to boost response rates and survival times due to two main reasons: (1) the high variability in the accumulation of nanomedicines in tumors and metastases; and (2) the poor tissue penetration of nanomedicines in tumors and metastases. Based on results of the ERC project NeoNaNo, we are developing an imageable and penetration-promoting PIcelles platform, which is based on polymeric micelles, that will tackle these challenges by incorporating three key features in one formulation: (1) chelators for radiolabeling, to enable patient pre-selection via non-invasive imaging of target site accumulation; (2) a novel peptide on the micelles’ shell, to allow for active targeting to the microenvironment in tumors and metastases, and also for active pharmacological promotion of nanomedicine penetration; and (3) facile, efficient and stable drug loading, with clinically relevant anticancer agents.

In this project, we aim to generate technical and commercial proof-of-concept for our proprietary PIcelles platform technology, enabling us to enter into license deals with large pharmaceutical industries that are in need of novel breakthrough drug delivery technologies for their difficult-to-formulate anticancer agents.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2018-PoC

See all projects funded under this call

Host institution

UNIVERSITAETSKLINIKUM AACHEN
Net EU contribution
€ 150 000,00
Address
Pauwelsstrasse 30
52074 Aachen
Germany
Region
Nordrhein-Westfalen Köln Städteregion Aachen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 150 000,00

Beneficiaries (1)